BridgeBio Pharma (BBIO) Other Non-Current Liabilities (2018 - 2026)

BridgeBio Pharma has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $229000.0 for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $229000.0, down 34.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $229000.0 (down 34.94% YoY), and the FY2025 annual result was $244000.0, down 14.69% from the prior year.
• Other Non-Current Liabilities came in at $229000.0 for Q1 2026 at BridgeBio Pharma, down from $244000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $28.6 million in Q2 2022 to a low of $229000.0 in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $679000.0 (2025), against an average of $9.6 million.
• Across the five-year window, Other Non-Current Liabilities surged 131.05% in 2022 and sank 96.8% in 2024, its largest moves.
• BridgeBio Pharma's Other Non-Current Liabilities stood at $26.6 million in 2022, then sank by 78.85% to $5.6 million in 2023, then slumped by 94.92% to $286000.0 in 2024, then slipped by 14.69% to $244000.0 in 2025, then dropped by 6.15% to $229000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $229000.0 (Q1 2026), $244000.0 (Q4 2025), and $679000.0 (Q3 2025), per Business Quant data.